Reviewer’s report

Title: A CASE OF MALIGNANT INSULINOMA RESPONSIVE TO SOMATOSTATIN ANALOGS TREATMENT

Version: 1 Date: 02 Aug 2018

Reviewer: Delphine Vezzosi

Reviewer's report:

Caliri et al described in this case report a patient with a malignant insulinoma in whom euglycemia was achieved with octreotide treatment.

This is an interesting manuscript. However I think that some points should be detailed to improve the quality of the manuscript

My comments are as follows

* Page 3, line 11: The authors mentioned, in the abstract that association with a MEN1 syndrome or age above 50 years are more frequent in malignant insulinomas.

* I think that this statement should be verified, in particularly for MEN1 and references added.

* Page 3, lines 54-56: 70 mg/dl can be a physiological blood glucose level. To my mind, it is not a "low glucose plasma level". This need to be corrected or discussed

* Page 4: line 19: The short octreotide test should be described: what is the dose of octreotide? Can the patient eat during the test? How long the test lasts?... etc

* Page 5, lines 1-5: What does "obtaining a good control of glycemia" mean? * Disappearance of clinical symptoms? Normalization of blood glucose levels documented by glucometer measurement? Normalization of blood glucose levels documented by Continuous Glucose Monitoring System?... This point should be detailed

* Page 7, lines 41-46: 111In-octreotide scintigraphy is not "the most effective imaging technique for the localization of insulinoma", as the authors said. The reported sensitivity of 111-In-octreotide scintigraphy for insulinoma localization is variably between 20 and 60% (Krenning et al 1993, De Herder et al 2005, Vezzosi et al 2005). 68Ga-DOTATATE PET/CT and Glucagon-like peptide-1 receptor could be efficient to localize insulinomas and authors should mention these new procedures.
Finally English should be corrected by a native speaker.

**Are the methods appropriate and well described?**  
If not, please specify what is required in your comments to the authors.

No

**Does the work include the necessary controls?**  
If not, please specify which controls are required in your comments to the authors.

Yes

**Are the conclusions drawn adequately supported by the data shown?**  
If not, please explain in your comments to the authors.

Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**  
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**  
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**  
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal